<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Conventional therapy with beta-blockers is incompletely effective in preventing arrhythmic events in patients with catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously discovered that flecainide in addition to conventional drug therapy prevents <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients with genotype-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To study the efficacy of flecainide in patients with genotype-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We studied the efficacy of flecainide for reducing <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> during exercise testing and preventing <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> events during long-term follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Twelve patients with genotype-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> were treated with flecainide </plain></SENT>
<SENT sid="5" pm="."><plain>Conventional therapy failed to control <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>Flecainide was initiated because of significant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (n = 8), <z:hpo ids='HP_0001279'>syncope</z:hpo> (n = 3), or <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> (n = 1) </plain></SENT>
<SENT sid="7" pm="."><plain>At the baseline exercise test before flecainide, 6 patients had <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> and 5 patients had bigeminal or frequent <z:mp ids='MP_0009732'>ventricular premature beats</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Flecainide reduced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> at the exercise test in 8 patients compared to conventional therapy, similar to that in patients with genotype-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> in our previous report </plain></SENT>
<SENT sid="9" pm="."><plain>Notably, flecainide completely prevented <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in 7 patients </plain></SENT>
<SENT sid="10" pm="."><plain>Flecainide was continued in <z:hpo ids='HP_0000001'>all</z:hpo> patients except for one who had <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> at the exercise test on flecainide </plain></SENT>
<SENT sid="11" pm="."><plain>During a follow-up of 48Â±94 months, <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> events (<z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> and aborted <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo>) associated with noncompliance occurred in 2 patients </plain></SENT>
<SENT sid="12" pm="."><plain>Flecainide was not discontinued owing to side effects in any of the patients </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Flecainide was effective in patients with genotype-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>, suggesting that spontaneous Ca(2+) release from <z:chebi fb="0" ids="8925">ryanodine</z:chebi> channels plays a role in <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> susceptibility, similar to that in patients with genotype-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
</text></document>